AI-ACCELERATED DRUG DISCOVERY

Focused On-demand Library for Glutathione S-transferase omega-1

Available from Reaxense
Predicted by Alphafold

Focused On-demand Libraries - Reaxense Collaboration

Explore the Potential with AI-Driven Innovation

This extensive focused library is tailor-made using the latest virtual screening and parameter assessment technology, operated by the Receptor.AI drug discovery platform. This technique is more effective than traditional methods, offering compounds with improved activity, selectivity, and safety.

From a virtual chemical space containing more than 60 billion molecules, we precisely choose certain compounds. Our collaborator, Reaxense, aids in their synthesis and provision.

Contained in the library are leading modulators, each labelled with 38 ADME-Tox and 32 physicochemical and drug-likeness qualities. In addition, each compound is illustrated with its optimal docking poses, affinity scores, and activity scores, giving a complete picture.

We use our state-of-the-art dedicated workflow for designing focused libraries for enzymes.

 Fig. 1. The sreening workflow of Receptor.AI

The procedure entails thorough molecular simulations of the catalytic and allosteric binding pockets, accompanied by ensemble virtual screening that factors in their conformational flexibility. When developing modulators, the structural modifications brought about by reaction intermediates are factored in to optimize activity and selectivity.

Our library is unique due to several crucial aspects:

  • Receptor.AI compiles all relevant data on the target protein, such as past experimental results, literature findings, known ligands, and structural data, thereby enhancing the likelihood of focusing on the most significant compounds.
  • By utilizing advanced molecular simulations, the platform is adept at locating potential binding sites, rendering the compounds in the focused library well-suited for unearthing allosteric inhibitors and binders for hidden pockets.
  • The platform is supported by more than 50 highly specialized AI models, all of which have been rigorously tested and validated in diverse drug discovery and research programs. Its design emphasizes efficiency, reliability, and accuracy, crucial for producing focused libraries.
  • Receptor.AI extends beyond just creating focused libraries; it offers a complete spectrum of services and solutions during the preclinical drug discovery phase, with a success-dependent pricing strategy that reduces risk and fosters shared success in the project.

partner

Reaxense

upacc

P78417

UPID:

GSTO1_HUMAN

Alternative names:

Glutathione S-transferase omega 1-1; Glutathione-dependent dehydroascorbate reductase; Monomethylarsonic acid reductase; S-(Phenacyl)glutathione reductase

Alternative UPACC:

P78417; D3DRA3; F5H7H0; Q5TA03; Q7Z3T2

Background:

Glutathione S-transferase omega-1 (GSTO1-1) plays a pivotal role in cellular defense mechanisms. It exhibits a range of activities, including glutathione-dependent thiol transferase, dehydroascorbate reductase, and S-(phenacyl)glutathione reductase activities. Furthermore, GSTO1-1 is involved in the biotransformation of inorganic arsenic, reducing harmful compounds like monomethylarsonic acid and dimethylarsonic acid. Its alternative names, such as Glutathione-dependent dehydroascorbate reductase and Monomethylarsonic acid reductase, reflect its diverse functions.

Therapeutic significance:

Understanding the role of Glutathione S-transferase omega-1 could open doors to potential therapeutic strategies. Its involvement in detoxification processes and reduction of arsenic compounds suggests its potential in treating arsenic poisoning and preventing arsenic-induced cellular damage.

Looking for more information on this library or underlying technology? Fill out the form below and we'll be in touch with all the details you need.
Thank you! Your submission has been received!
Oops! Something went wrong while submitting the form.